Another Post-Trump Trade: Revisiting Sun Pharmaceuticals (SUNP IN) After Q2 (FY2017) Earnings
We initiated coverage on Sun Pharmaceutical Indus (SUNP IN) with Buy rating and common stock price target of INR 855 earlier this month. Link to...
182 Views
President Trump and Healthcare (And Pharma) Sector: What's Next?
Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare...
256 Views
Sun Pharmaceuticals: Time To Buy This World Class Pharma Company On This Pullback.
Sun Pharmaceutical Indus (SUNP IN) is the fifth largest Specialty Pharmaceuticals and Generics company in the world. It is the largest...
410 Views
Key Drivers of Asia's Healthcare Sector
From a demand perspective, Asia’s population is growing as is longevity. On the supply side, Asia’s number of doctors, nurses, hospitals and...
3.4k Views
ANIMAL SPIRITS™ REPORT: India Equity Strategy - Upgrade To Overweight as Patel's Dovish Arm Twists
Investment Conclusions - Tactical View (3-6 Months) Animal Spirits prefers an "overweight" stance on Indian equities. Our macro baseline scenario...
401 Views